KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Long-Term Deferred Tax (2016 - 2025)

Astrazeneca (AZN) has 3 years of Long-Term Deferred Tax data on record, last reported at $8.0 billion in Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax rose 49.6% year-over-year to $8.0 billion; the TTM value through Dec 2025 reached $8.0 billion, up 49.6%, while the annual FY2025 figure was $8.0 billion, 49.6% up from the prior year.
  • Long-Term Deferred Tax reached $8.0 billion in Q4 2025 per AZN's latest filing, up from $5.3 billion in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $8.0 billion in Q4 2025 and bottomed at $4.7 billion in Q4 2023.
  • Average Long-Term Deferred Tax over 3 years is $6.0 billion, with a median of $5.3 billion recorded in 2024.
  • Peak YoY movement for Long-Term Deferred Tax: grew 13.33% in 2024, then surged 49.6% in 2025.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $4.7 billion in 2023, then grew by 13.33% to $5.3 billion in 2024, then surged by 49.6% to $8.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Deferred Tax were $8.0 billion in Q4 2025, $5.3 billion in Q4 2024, and $4.7 billion in Q4 2023.